Offer for a New York Times All Access subscription; current subscribers not eligible. Subscription excludes print edition. For a monthly subscription, your payment method will automatically be charged in advance the introductory rate every 4 weeks for 1 year, and after 1 year the standard rate every 4 weeks. For an annual subscription, your payment method will automatically be charged in advance the introductory rate for 1 year, and after 1 year the standard rate once yearly. Your subscription will continue until you cancel. Cancellation takes effect at the end of your current billing period. Taxes may apply. Offer terms are subject to change.
To stop receiving our updates and offers, unsubscribe. To opt out of newsletters and other promotional emails from The Times, manage your email preferences.
Zepbound is the first prescription drug approved specifically to treat the common condition. View in browser Dec. 20, 2024, 5:22 p.m. ET BREAKING NEWS Dustin Chambers for The New York Times F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder. Read more Need help? Review our newsletter help page or contact us for assistance. You received this email because you signed up for Breaking News from The New York Times. To stop receiving Breaking News, unsubscribe . To opt out of other promotional emails from The Times, including those regarding The Athletic, manage your email settings . To opt out of updates and offers sent from The Athletic, submit a request . Subscribe to The Times Get The New York Times app Connect with us on: Change Your Email Privacy Policy Contact Us Califo...
The Stories Behind: The one-eyed tattoo artist who won't let a rare disease affect his craft Dear readers, From Oct 1, TODAY will merge with CNA and become the digital long-form weekend magazine CNA TODAY. You can head to cna.asia for our best offerings including inspiring human interest stories, in-depth features focusing on Singapore and beyond, deep dives into the issues that matter with our Big Reads, and columns on helping adults of all ages navigate the complexities of life. We will be sending out a refreshed newsletter next Sunday, so do remain subscribed to us. You can also check out our social media channels on Instagram, Facebook, Telegram and WhatsApp for our offerings. Thank you for your support. Sunday, 29 September 2024 The Big Read: It's become increasingly difficult to smoke outdoors, but some way yet before Singapore is smoke-free ...